| 9/18/09 | Lead Inventor: Solder Formulation and use in Tissue Welding |
| U.S. Pat. Non-Provisional Filing (PCT/US2009/057419, Univ. of Pennsylvania) | |
| Novel solder formulation for use in laser tissue welding which allows for the creation of instant, sutureless, endoscopic and open wound repair. This patent is currently under review and is being actively explored for licensing by two device companies. | |
| 9/21/09 | Co-Inventor: Chitosan Based Stents, Spacers, and Implants for use in Rhinologic Pathologies |
| U.S. Pat. Non-Provisional Filing (Docket P71335, Univ. of Pennsylvania) | |
| Drug eluting hydrogel which can be used to design implantable sinonasal therapies which can improve local therapeutic efficacy while limiting systemic exposure. This application was eventually abandoned after assessment that the intellectual property space was too crowded to ensure a successful application. | |
| U.S. Patent No. 8,673,338 | A method of delivering at least one pharmaceutical agent to the central nervous system of a subject, the method comprising directly administering at least one pharmaceutical agent onto a semipermeable epithelial membrane (SEM) graft in the skull base of the subject). |
| U.S. Patent No. 8,945,600 | A method of delivering at least one pharmaceutical agent to the central nervous system of a subject diagnosed with Parkinson’s disease, the method comprising directly administering at least one pharmaceutical agent onto a semipermeable epithelial membrane (SEM) graft in the skull base of the subject. |
| U.S. Patent No. 9,084,756 | A method of delivering at least one pharmaceutical agent to the central nervous system of a subject diagnosed with Alzheimer’s disease, the method comprising directly administering at least one pharmaceutical agent onto a semipermeable epithelial membrane (SEM) graft in the skull base of the subject. |
| U.S. App. No. 14/739,872 | A method of delivering at least one pharmaceutical agent to the central nervous system of a subject diagnosed with a brain cancer, the method comprising directly administering at least one pharmaceutical agent onto a semipermeable epithelial membrane (SEM) graft in the skull base of the subject. |
| U.S. App. No. 15/069,647 | A method of delivering at least one pharmaceutical agent to the central nervous system of a subject diagnosed with stroke, the method comprising directly administering at least one pharmaceutical agent onto a semipermeable epithelial membrane (SEM) graft in the skull base of the subject. |
| Treatment of Rhinosinusitis with P-Glycoprotein Inhibitors (MEE 2012-272) | First Independent Claim |
| U.S. Application 14/655,662 | A method of treating rhinosinusitis in a subject, the method comprising: identifying a subject having rhinosinusitis; administering to the subject an effective amount of a P-glycoprotein inhibitor. |
| EP Application 13866961.9 | Available on request. |
| HK registration through 13866961.9 | Identical to EP app |
| Secreted P-Glycoprotein is a non-invasive biomarker of chronic rhinosinusitis (MEE 2015-580) | First Independent Claim |
| US Provisional 62/279,590 | A method of diagnosing Chronic Rhinosinusitis (CRS) in a subject, the method comprising: providing a sample comprising nasal secretions, e.g., nasal mucus from a subject; determining a level of soluble p-glycoprotein (P-gp) in the sample; and comparing the level of P-gp in the sample to a reference level of P-gp; wherein a level of P-gp in the sample above the reference level indicates that the subject has CRS. |
Menu